Sign Up For News And Updates

Your Contact Information
First Name:
Last Name:
E-mail Address:
Sign up for the following:






Your Address
Address:
City:
State:
ZIP:
Mobile Phone:
Learn more about opt-in
By checking this box, you agree to receive email and text message updates from us. By checking this box, I consent to receive event and news updates via email and SMS. Unsubscribe anytime via provided links. Your information is safe with us and used solely for providing our News and updates. Standard Msg & Data rates may apply.
Update on Move to New Building

Viral Hemorrhagic Fever

What is viral hemorrhagic fever?

Includes: Ebola, Marburg, Lassa, New World Arenavirus, Crimean-Congo, Rift Valley Fever, Dengue Fever, Yellow Fever, Omsk Hemorrhagic Fever, or Kyasanur Forest Disease

Viral hemorrhagic fevers are rare diseases in the United States but more prevalent in Africa. They are caused by four classes of viruses (Filoviruses, Arenaviruses, Bunyaviruses, and Flaviviruses). Humans are incidentally infected by a bite of an infected tick or mosquito, via aerosol generated from an infected rodent excretia, or by direct contact with infected animal carcasses. With the exception of Rift Valley fever and the diseases caused by Flaviviruses (Yellow fever, Omsk HF, and Kyasanur Forest Disease) which are not transmissible person-to-person, infected humans can spread the disease to close contacts by touching bodily fluids, which may result in community outbreaks and nosocomial infections. Person-to-person transmission by respiratory droplets through the air appears to be rare but cannot be ruled out. With intentional exposure, as in a bioterrorist release, breathing in airborne virus, or touching a substance with the virus and transferring it to the mucous membranes in the eyes or mouth are the most likely routes of entry into the body.

What are the symptoms of VHFs?

Clinical symptoms and signs of VHFs may include early onset of symptoms lasting for less than 1 week including fever, nausea and vomiting, joint and muscle pain, headache, extreme weakness, lack of strength, fatigue, sore throat, cough, chest and abdominal pain, and nonbloody diarrhea. Early signs also include slowing of pulse rate, rapid respiration, conjunctivitis, pharyngitis, weight loss, difficulty swallowing, shortness of breath, and for some VHFs, a rash. Later patients may show signs of bleeding of gums, vomiting blood, bloody stool, blood in urine, excessive bleeding at puncture sites, nose bleed, or blood in sputum.

How soon after exposure would symptoms begin?

Symptoms generally develop between 2 and 21 days after exposure.

Can VHFs be spread person-to-person?

Yes. Hemorrhagic fever viruses are highly contagious by touching bodily fluids of infected patients and then touching your mouth or eyes. Strict barrier precautions for infection control should be taken to prevent direct contact with infected patients.

How likely is it that I will be exposed to VHFs, or other biological or chemical agents?

There has never been a case of VHF in WV. Historically, in the United States, the individual risk of disease from a bioterrorist event has been very, very low.

What will be done to evaluate an incident?

State and local public health, emergency, and law enforcement agencies will work together to evaluate all incidents. Examining the circumstances of the incident, the suspect material, and the type of exposure is required to determine if the incident represents a public health risk.

Viral Hemorrhagic Fever Information for Public Health Officials

A Group of Viruses

Unique Epidemiological Characteristics

  • No natural reservoir in West Virginia
  • A newly reported case should be urgently investigated considering:
    • travel
    • BT
  • Incubation: 2-21 days
  • Mortality: .5 to 90%, depending on the agent – Emergency
  • Person-to-person transmission: by direct contact; possibly by aerosol
  • Environmental: these lipid-enveloped viruses are not expected to be environmentally hardy; expert consultation recommended
  • Prophylaxis: none
  • Treatment: ribavirin (experimental) for arenaviruses or bunyaviridae

Laboratory confirmation:

  • CDC / USAMRIID
  • Implications: use a clinical case definition to confirm cases during the early part of a reported outbreak

Employee health

  • Employees who will have direct patient contact should be supplied with an N-95 mask or a powered air-purifying respirator, gloves, gowns, eye protection, etc.

Lifesaving interventions – in order:

  1. Recognition / reporting / case-finding + aerosol and contact isolation
  2. Identification + recommendations for treatment (if appropriate)

Training considerations:

  • Physicians: recognition / reporting / isolation / treatment
  • ICPs: reporting, active surveillance procedures, isolation
  • Local health departments, regional epidemiologists: Investigation / isolation
  • IDEP / DSDC / BPH: investigation / communication / prioritization of control measure

CDC–Viral Hemorrhagic Fever Page